Latest MDL 2846 News: Bard Hernia Mesh Lawsuit Updates and Settlement Progress

Thousands of patients who received C.R. Bard or Davol polypropylene hernia mesh have faced years of chronic pain, infections, mesh migration, and revision surgeries. Over one million hernia repairs occur annually in the United States, and complication rates for polypropylene mesh products often reach 10 to 15 percent. If you or a loved one received one of these implants and later needed additional procedures, the latest MDL 2846 news offers both context and potential paths forward.

This article delivers a clear, up-to-date overview of the federal multidistrict litigation known as In re: Davol, Inc./C.R. Bard, Inc., Polypropylene Hernia Mesh Products Liability Litigation. It covers the current case count, the 2024 global settlement framework, settlement administration progress, bellwether trial history, eligibility considerations, and practical next steps. The goal is to help affected patients and their families understand where the litigation stands in October 2026 and what options remain available.

What Is MDL 2846 and Why It Matters

MDL 2846 consolidates federal product liability lawsuits involving polypropylene hernia mesh devices manufactured by Davol Inc. and C.R. Bard Inc. (now part of Becton, Dickinson and Company, or BD). The Judicial Panel on Multidistrict Litigation centralized these cases in the U.S. District Court for the Southern District of Ohio in August 2018. Judge Edmund A. Sargus Jr. oversees the proceedings, with Magistrate Judge Kimberly A. Jolson assisting.

An MDL is not a class action. Each plaintiff’s case remains individual. The court coordinates pretrial discovery, expert testimony, and rulings on common issues such as design defect and failure to warn. This structure reduces duplication and allows the parties to evaluate the overall strength of the claims through selected test cases called bellwether trials.

As of early October 2026, the docket shows approximately 23,324 pending actions and more than 25,200 total actions filed over the life of the MDL. These figures make MDL 2846 the largest active medical device multidistrict litigation and one of the largest MDLs overall. Many of the pending cases are in settlement administration rather than active pretrial discovery. BD has publicly stated that it was defending roughly 7,090 hernia claims as of mid-2026 and that no trials are currently scheduled.

The products at issue include a range of Bard and Davol polypropylene meshes. Common names that appear in court filings and medical records include Ventralight ST, Ventralex, Ventralex ST, PerFix Plug, 3DMax, Composix, Sepramesh, and Kugel mesh lines. Plaintiffs allege these devices can shrink, migrate, adhere to organs, cause chronic inflammation, or lead to infection and hernia recurrence. Many claimants underwent one or more revision surgeries to remove or repair the mesh.

The Path to Settlement: Bellwether Trials and Court Direction

Before the global settlement framework, the court conducted several bellwether trials to test how juries would respond to the evidence. Results were mixed, which is typical in mass tort litigation and often accelerates settlement talks.

The first federal bellwether, Johns v. C.R. Bard (involving Ventralight ST), ended in a defense verdict in 2021. Subsequent trials produced plaintiff verdicts. Milanesi resulted in a $255,000 award in 2022. Stinson, involving an XL PerFix Plug that had balled up and required removal, produced a $500,000 verdict in late 2023 on a failure-to-warn theory. A separate Rhode Island state court trial involving a Ventralex product yielded a $4.8 million plaintiff verdict in 2022.

In early 2024, Judge Sargus indicated that further bellwether trials would not proceed and directed the parties to focus on resolution. That direction set the stage for the announcement that followed later that year.

Global Settlement Framework Announced in 2024

In October 2024, BD announced a global settlement framework intended to resolve the vast majority of its existing hernia mesh litigation. Reports indicate the agreement covers roughly 38,000 claims across the federal MDL and the parallel Rhode Island state court consolidation. BD stated that the financial terms fell within its existing product liability reserves and that the settlement did not constitute an admission of liability or wrongdoing.

Specific dollar amounts and detailed payout grids remain confidential. Public reporting has placed the overall value in the range of $1 billion or higher, consistent with the size of the company’s litigation reserves at the time. Payments are structured over multiple years rather than as a single lump-sum distribution.

Two important Case Management Orders followed the announcement. Case Management Order 55 (November 2024) appointed Special Masters Ellen K. Reisman and John Jackson and established an Intensive Settlement Process for claims that do not resolve under the main framework. Sessions under that process are scheduled to begin on or about January 4, 2027, with a June 1, 2029 opt-out checkpoint. Case Management Order 56 (December 2024) created a Qualified Settlement Fund to hold and administer settlement payments.

Subsequent orders have refined procedures for funding the Qualified Settlement Fund and handling common benefit assessments. As of mid-to-late 2026, the litigation sits primarily in administration mode. Hundreds of cases have been resolved since early 2025, yet the docket count remains high because many claims continue to move through documentation review and payment processing.

Settlement Administration and What Claimants Can Expect

Settlement administration in a mass tort of this size is rarely instantaneous. Claimants typically must submit medical records that confirm the specific Bard or Davol product implanted, the date of the original surgery, and any subsequent complications or revision procedures. Operative reports, pathology results, imaging studies, and physician notes linking the complications to the mesh carry significant weight.

Reported tier structures (when available from secondary sources) generally reward stronger documentation of serious injuries such as adhesions requiring surgery, bowel obstruction, infection, mesh migration, or multiple revisions. Claims with limited records or milder complications may fall into lower categories or quick-pay options. Net recoveries after attorney fees, medical liens, and expenses are typically lower than the gross award figures sometimes discussed online.

The Intensive Settlement Process scheduled for 2027 provides a court-supervised path for unresolved claims, including certain opt-outs and later-filed cases that meet agreed criteria. Claimants who ultimately reject offers under the main framework or the Intensive Settlement Process retain the right to pursue individual litigation, subject to applicable statutes of limitations and court procedures.

New cases continue to be filed and transferred into the MDL. Law firms that remain active in this litigation have become more selective, often prioritizing cases with clear product identification and documented revision surgery. Statutes of limitations vary by state and frequently incorporate a discovery rule, meaning the clock may start when the patient reasonably connected the complications to the mesh rather than the date of the original implant.

Common Complications and Why Patients File Claims

Patients who pursue these cases typically describe a similar pattern. After the initial hernia repair, recovery does not progress as expected. Pain persists or intensifies. Imaging reveals mesh shrinkage, migration, or dense adhesions to bowel or other organs. Infection develops. In many instances, surgeons recommend or perform revision surgery to remove as much of the mesh as possible or to repair damage caused by the implant.

Revision surgery itself can be complex. Complete removal is not always possible, and some patients face ongoing symptoms even after the second procedure. These real-world experiences form the core of the claims consolidated in MDL 2846. The litigation does not assert that every hernia mesh product is defective or that every patient will experience problems. It focuses on allegations that certain polypropylene designs and coatings carried risks that were not adequately disclosed and that those risks materialized in significant numbers of patients.

How to Determine Whether You May Have a Claim

Eligibility is fact-specific. General considerations that attorneys examine include:

Confirmed implantation of a Bard or Davol polypropylene hernia mesh product (product name and manufacturer should appear in the operative report or implant records).
Surgery date roughly on or after January 1, 2006 (earlier cases may face additional hurdles).
Documented complications occurring more than 30 days after the original implant, such as chronic pain, infection, adhesions, bowel obstruction, mesh migration, organ perforation, or hernia recurrence.
Medical records that connect the complications to the mesh, ideally including revision surgery reports.
Timely filing under the applicable state statute of limitations.

Even if your case was not part of the original 2024 settlement inventory, the MDL remains open and the Intensive Settlement Process offers a potential avenue. The only reliable way to evaluate a specific situation is through a review of medical records by an attorney experienced in this litigation.

Practical Steps for Patients and Families

If you believe you may have a claim, begin by gathering records. Request the complete operative report from the original hernia repair and any subsequent procedures. Ask for pathology reports if mesh was removed. Obtain imaging studies and notes from treating physicians that discuss the mesh. Create a simple timeline of symptoms and treatments.

Next, consult a lawyer who handles hernia mesh cases. Many firms offer free initial reviews. Be prepared to discuss the product name if known, the dates of surgeries, and the nature of your complications. An attorney can explain whether your case fits within existing settlement processes, whether a new filing makes sense, and how statutes of limitations apply in your state.

Avoid relying solely on social media posts or unverified settlement calculators. Actual recoveries depend on documentation quality, injury severity, liens, and the specific terms of any applicable agreement. Patience is often required; multi-year payment schedules are common in large settlements.

For medical questions, continue working with your physicians. Legal claims do not replace ongoing medical care. If you experience new or worsening symptoms, seek evaluation promptly.

Looking Ahead: What the Coming Months May Bring

The Intensive Settlement Process beginning in early 2027 represents the next major phase for unresolved claims. Special Masters will oversee conference sessions aimed at resolving remaining cases. The June 2029 opt-out checkpoint will give certain claimants a formal opportunity to decide whether to accept resolution terms or return to individual litigation.

Meanwhile, the docket continues to see modest numbers of new filings and gradual case closures. BD’s public disclosures indicate the company is managing the remaining inventory without scheduled trials. This environment favors administrative resolution over further large-scale courtroom testing.

Patients who have already submitted claims should maintain contact with their counsel and respond promptly to requests for additional records or information. Those who have not yet explored their options still have time in many jurisdictions, but waiting carries risk because statutes of limitations continue to run.

Frequently Asked Questions

What is the current number of pending cases in MDL 2846?
As of early October 2026, approximately 23,324 actions remain pending according to Judicial Panel on Multidistrict Litigation statistics. The high number largely reflects cases moving through settlement administration rather than active pretrial discovery.

Has a final global settlement amount been publicly disclosed?
No. BD announced a framework in October 2024 covering roughly 38,000 claims and stated that the terms fell within its reserves. Detailed payout figures and grids have not been released publicly.

When will settlement payments begin or continue?
A Qualified Settlement Fund was established in late 2024. Administration is ongoing. Full distribution for many claims is expected to span several years. The Intensive Settlement Process for unresolved claims begins around January 2027.

Can I still file a new lawsuit?
Yes. The MDL remains open. New cases continue to be filed and transferred, subject to statutes of limitations and the strength of the medical evidence.

Do I need to have had revision surgery to have a claim?
Revision surgery significantly strengthens a claim and is present in the majority of cases being actively pursued. Documented complications without revision may still support a claim in some circumstances, but they are evaluated more carefully.

Which Bard products are most commonly involved?
Ventralight ST, Ventralex and related ST versions, PerFix Plug, 3DMax, Composix, Sepramesh, and certain Kugel products appear frequently. Product identification comes from operative records.

How long does the process usually take from filing to resolution?
Timelines vary widely. Cases that entered the 2024 framework may resolve on multi-year payment schedules. Newer or unresolved cases may proceed through the 2027 Intensive Settlement Process or individual litigation.